帕博利珠单抗联合GVD方案作为复发或难治性经典型霍奇金淋巴瘤二线治疗的II期试验
该II期研究评估帕博利珠单抗联合吉西他滨、长春瑞滨和脂质体多柔比星(pembro-GVD)用于移植 eligible 的复发或难治性经典型霍奇金淋巴瘤二线治疗。38例可评估患者中总缓解率100%,完全缓解率95%,36例(95%)成功桥接至大剂量化疗和自体造血干细胞移植,移植后中位随访13.5个月所有移植患者均处于缓解。
要点
- pembro-GVD方案在复发/难治性cHL中完全缓解率达95%
- 95%患者成功桥接至HDT/AHCT,移植后中位随访13.5个月全部缓解
- 多数不良事件为1-2级,3级不良事件包括转氨酶升高和中性粒细胞减少
核心结论
- pembro-GVD作为复发/难治性cHL的二线治疗高效且耐受良好,能有效桥接患者至HDT/AHCT。
研究设计与样本
- II期研究纳入39例一线治疗后复发/难治且适合移植的cHL患者,接受2-4周期pembro-GVD(21天为一周期)。
- 主要终点为最多4周期pembro-GVD后的完全缓解率。
主要发现
- 38例可评估患者中,pembro-GVD后总缓解率为100%,完全缓解率为95%。
- 36例(95%)患者接受HDT/AHCT,2例在HDT/AHCT前接受累及部位放疗,13例(33%)在HDT/AHCT后接受维布妥昔单抗维持治疗。
- 所有36例移植患者在中位移植后随访13.5个月(范围2.66-27.06个月)时均处于缓解。
- 大多数不良事件为1级或2级,3级不良事件包括转氨酶升高(n=4)、中性粒细胞减少(n=4)、黏膜炎(n=2)、甲状腺炎(n=1)和皮疹(n=1)。
关键数值与推荐
- 帕博利珠单抗200 mg静脉注射第1天,吉西他滨1000 mg/m2第1、8天,长春瑞滨20 mg/m2第1、8天,脂质体多柔比星15 mg/m2第1、8天,21天为一周期。
- 完全缓解定义为Deauville评分≤3的FDG-PET。
临床怎么用
- pembro-GVD可作为复发/难治性cHL患者的二线治疗方案,有效桥接至HDT/AHCT。
局限性
- 样本量较小(39例),随访时间较短(中位13.5个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT03618550). METHODS: Transplant eligible patients with rel/ref cHL following first-line therapy were treated with two to four cycles of pembrolizumab (200 mg intravenous [IV], day 1), gemcitabine (1,000 mg/m2 IV, days 1 and 8), vinorelbine (20 mg/m2 IV, days 1 and 8), and liposomal doxorubicin (15 mg/m2, days 1 and 8), given on 21-day cycles. The primary end point was complete response (CR) following up to four cycles of pembro-GVD. Patients who achieved CR by labeled fluorodeoxyglucose-positron emission tomography (Deauville ≤ 3) after two or four cycles proceeded to high-dose therapy and autologous hematopoietic cell transplantation (HDT/AHCT). HDT/AHCT was carried out according to institutional standards, and brentuximab vedotin maintenance was allowed following HDT/AHCT. RESULTS: Of 39 patients enrolled, 41% had primary ref disease and 38% relapsed within 1 year of frontline treatment. 31 patients received two cycles of pembro-GVD, and eight received four cycles. Most adverse events were grade 1 or two, whereas few were grade 3 and included transaminitis (n = 4), neutropenia (n = 4), mucositis (n = 2), thyroiditis (n = 1), and rash (n = 1). Of 38 evaluable patients, overall and CR rates after pembro-GVD were 100% and 95%, respectively. Thirty-six (95%) patients proceeded to HDT/AHCT, two received pre-HDT/AHCT involved site radiation, and 13 (33%) received post-HDT/AHCT brentuximab vedotin maintenance. All 36 transplanted patients are in remission at a median post-transplant follow-up of 13.5 months (range: 2.66-27.06 months). CONCLUSION: Second-line therapy with pembro-GVD is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to HDT/AHCT.
引用
- Moskowitz AJ, Shah G, Schöder H, et al. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. J Clin Oncol. 2021. PMID: 34170745. doi:10.1200/JCO.21.01056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。